<DOC>
	<DOCNO>NCT02575079</DOCNO>
	<brief_summary>The purpose study see apply parafilm external barrier central line child bone marrow transplant help prevent central line associate bloodstream infection ( ) also assess ease use parafilm .</brief_summary>
	<brief_title>Parafilm Prevent CLABSI Pediatric Patients Undergoing HCT</brief_title>
	<detailed_description>Central line associate bloodstream infection ( CLABSI ) result significant morbidity mortality , particularly patient undergo hematopoietic cell transplantation ( HCT ) . HCT patient high risk CLABSI due multiple factor , include prolong immune suppression need long-term central venous access . The investigator want assess feasibility use parafilm central line barrier ( parafilm ) standard care pediatric HCT patient . The investigator also assess effectiveness parafilm reduce incidence CLABSI patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<criteria>Must age 0 21 year time enrollment Must undergo allogeneic autologous HCT malignant nonmalignant disorder Must schedule tunnel CVC Patients undergoing intervention prevent CLABSI ( e.g . Children 's Oncology Group ( COG ) study ACCL1034 Chlorhexidine Gluconate ( CHG ) ; antimicrobial lock therapy , etc . ) Patients port</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>